Abstract
AbstractMeningiomas represent the most frequently diagnosed intracranial tumors. Inflammatory cells present in the tumor can modulate both antitumor and protumor functions, and modify the therapeutic response. Hematological inflammatory parameters have provided prognostic information useful in the treatment and clinical evaluation of several tumors. The aim of this study was to evaluate preoperative hematological markers of patients with meningiomas and to relate them to clinical variables and recurrence-regrowth free survival. Eighty-nine patients without corticosteroid therapy were included. Blood test results and tumor characteristics were collected from medical records. Associations between clinical characteristics and the recurrence-regrowth free survival (RFS) were evaluated using Cox proportional hazard analysis and Kaplan-Meier curves. The receiver operating characteristic (ROC) curves were constructed. Of the 89 cases, 73 (82%) were grade I and 16 (18%) grade II. The mean age was 53 ± 13.9 years, with higher frequency in women. Anemia was observed in 23.6% and neutrophilia in 42% of the patients. In univariate analysis, anemia (p = 0.04), neutrophilia (p = 0.02) and neutrophil/lymphocyt ratio (NLR) (p = 0.02) were associated with an increased risk of recurrence-regrowth and shorter RFS. In multivariate analysis, anemia and NLR > 4.1 represented a higher risk of recurrence-regrowth (p = 0.003). The ROC curve analysis showed that only the lymphocyte/monocyte (L/M) > 2.5 was able to predict the tumor grade. The preoperative presence of anemia, neutrophilia, NLR > 4.1 and L/M > 2.5 were associated with a worse prognosis in meningiomas. The use of preoperative hematological inflammatory parameters as prognostic factors can be promissing for evaluation and follow-up of meningiomas.
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Abbritti RV, Polito F, Cucinotta M, Lo Giudice C, Caffo M, Tomasello C, Germanò A, Aguennouz M. Meningiomas and proteomics: focus on new potential biomarkers and molecular pathways. Cancer Genomic Proteomic. 2016;13:369–79.
2. Albini A, Bruno A, Noonan D, Mortara L. Contribution to tumor angiogenesis from innate immune cells with int he tumor microenvironment: implications for immunotherapy. Front Immunol. 2018;9:527. https://doi.org/10.3389/fimmu.2018.00527.
3. Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018;18(3):241–9. https://doi.org/10.1080/14737175.2018.1429920.
4. Azar M, Kazemi F, Jahanbakhshi A, Chanideh I, Jalessi M, Amini E, Geraily G, Farhadi M. Gamma knife radiosurgery for cavernous sinus meningiomas: analysis of outcome in 166 patients. Stereotact Funct Neurosurg. 2017;95(4):259–67. https://doi.org/10.1159/000478024.
5. Balasubramanian SK, Sharma M, Silva D, Karivedu V, Schmitt P, Stevens GH, Barnett GH, Prayson RA, Elson P, Suh JH, Murphy ES, Chao ST. Longitudinal experience with WHO grade III (anaplastic) meningiomas at a single institution. J Neuro Oncol. 2017;131(3):555–63. https://doi.org/10.1007/s11060-016-2321-8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献